RSNA 2019

Abstract Archives of the RSNA, 2019


VI214-SD-WEA3

Effects of Oxytocin on High-Intensity Focused Ultrasound Ablation of Leiomyoma: A Clinical Trial Study

Wednesday, Dec. 4 12:15PM - 12:45PM Room: VI Community, Learning Center Station #3



FDA Discussions may include off-label uses.

Participants
Nguyen Minh Duc, MD, Ho Chi Minh, Vietnam (Presenter) Nothing to Disclose
Rajiv Chopra, PhD, Dallas, TX (Abstract Co-Author) Stockholder, Profound Medical Corporation; Stockholder, Solenic Medical Inc
Bilgin Keserci, PhD, Kota Bharu, Malaysia (Abstract Co-Author) Nothing to Disclose

For information about this presentation, contact:

bsnguyenminhduc@pnt.edu.vn

PURPOSE

To investigate the impact of oxytocin on high-intensity focused ultrasound (HIFU) ablation for the treatment of leiomyoma.

METHOD AND MATERIALS

This clinical trial study was approved by institutional review board. 40 patients with symptomatic leiomyoma underwent HIFU treatment. They were divided into two groups based on perfusion classification: group A (n = 20, if time-signal intensity curve of leiomyoma lower than that of myometrium regarded as weak perfusion group) and group B (n = 20, if time-signal intensity curve of leiomyoma equal to or higher than that of myometrium). Groups A and B was subdivided into two subgroups A1 (n = 10), B1 (n = 10) (with only intravenous infusion normal saline) considered as control group and two subgroups A2 (n = 10), B2 (n = 10) with intravenous infusion oxytocin 0.2 U/min (with 500 ml of 0.9% normal saline added 60 units of oxytocin running at the rate of 2 ml/min) considered as oxytocin group. Treatment results, adverse events were compared.

RESULTS

The mean non-perfused volume ratio (NPVr) of groups A and B was 92% 18 and 67% 24 (p<0.05). The mean power of groups A and B was 160W 28 and 200W 34 (p<0.05). The mean time treatment of groups A and B was 134minute 12 and 155minute 30 (p<0.05). The mean NPVr of subgroup A1 and A2 was 93% and 90% (p>0.05). The mean power of subgroups A1 and A2 was 158W and 164W (p>0.05). The mean treatment time of subgroup A1 and A2 was 126minute and 138minute (p>0.05). The mean NPVr of subgroup B1 and B2 was 72% and 60% (p<0.05). The mean power of subgroup B1 and B2 was 192W and 222W (p<0.05). The mean treatment time of subgroup B1 and B2 was 140minute and 168minute (p<0.05). There were no differences in adverse events between group A and group B, subgroups A1 and A2, B1 and B2. There were no oxytocin-related adverse events reported.

CONCLUSION

Oxytocin could solely improve the treatment efficacy by reducing the power, enhancing the treatment speed, thus achievement of higher NPVr for patients with strong perfusion leiomyoma.

CLINICAL RELEVANCE/APPLICATION

The clinicians should take oxytocin into consideration during ablation procedure in cases of strong perfusion leiomyoma to obtain better HIFU outcomes for patients.

Printed on: 03/01/22